Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease

Circulation

Volumn 101, Issue 19, 2000, Pages 2252-2257

  James, Richard W ^a,b   Leviev, Ilia ^a   Righetti, Alberto ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antioxidants; Coronary disease; Factors; Lipoproteins; Risk; Smoking

Indexed keywords

ARYLDIALKYLPHOSPHATASE; CIGARETTE SMOKE; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; SMOKING CESSATION;

EID: 0034673981     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.19.2252     Document Type: Article

References (45)

1. Blatter M-C, James RW, Messmer S, et al. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45: identity of K-45 with paraoxonase. Eur J Biochem. 1993;211:871-879.
2. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286: 152-154.
3. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidised low density lipoprotein. J Clin Invest. 1995;96:2882-2891.
4. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581-1590.
5. Shin DM, Gu L, Xia Y-R, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284-287.
6. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963-20966.
7. Ruiz J, Blanché H, James RW, et al. The polymorphism (Gln-Arg192) of the high-density lipoprotein-bound enzyme paraoxonase is an independent cardiovascular risk factor in non-insulin dependent diabetic patients. Lancet. 1995;346:869-872.
8. Blatter Garin M-C, James RW, Dussoix P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme: a possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest. 1997; 99:62-66.
9. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary heart disease. J Clin Invest. 1995;96:3005-3008.
10. Odawara M, Tachi Y, Yamashita K. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetic patients. J Clin Endocrinol Metab. 1997; 82:2257-2260.
11. Sanghera DK, Sana N, Aston CE, et al. Genetic polymorphisms of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol. 1997;17:1067-1073.
12. 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol. 1997;17:3565-3569.
13. Pfohl M. Koch M, Enderle MD, et al. Paraoxonase: Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes. 1999;192:48:623-627.
14. Antikainen M, Murtomaki S. Syvänne M, et al. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with risk of coronary artery disease in Finns. J Clin Invest 1996; 98:883-885.
15. Herrmann S-M, Blanc H, Poirier O, et al. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis. 1996;126:299-304.
16. Scheffler E, Wiest E, Woehrle J, et al. Smoking influences the atherogenic potential of low density lipoprotein. J Clin Invest 1992;70: 263-268.
17. Pryor WA, Stone K. Oxidants in cigarette smoke: radicals, hydrogen peroxide, peroxynitrate and peroxynitrite. Ann N Y Acad Sci. 1993;686: 12-27.
18. Morrow JD, Frei B, Longmire AW, et al. Increases in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smokjng as a cause of oxidative damage. N Engl J Med. 1995;332:1198-1203.
19. Yokode M, Kita T, Arai H, et al. Cholesterol ester accumulation in macrophages incubated with low density lipoprotein pretreated with cigarette smoke extract. Proc Natl Acad Sci U S A. 1988;85:2344-2348.
20. Harats D, Ben-Naim M, Dabach Y, et al. Cigarette smoke renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages. Atherosclerosis. 1989;79:245-252.
21. Heitzer T, Yla-Herttuala S, Luoma J, et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia: role of oxidized LDL. Circulation 1996;93: 1346-1353.
22. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation 1995; 91:2488-2496.
23. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
24. Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun. 1997;236:289-293.
25. James RW, Pometta D. Differences in lipoprotein subfraction composition and distribution between type 1 diabetic men and control subjects. Diabetes. 1990;39:1158-1164.
26. James RW, Pometta D. The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1991;34:246-252.
27. Puhl H, Waeg G, Esterbauer H. Methods to determine oxidation of low-density lipoproteins. Methods Enzymol. 1994;233:425-441.
28. Wolff SP. Ferrous ion oxidation in presence of ferric ion indicator xylenol orange for measurement of hydroperoxides. Methods Enzymol. 1994;233: 182-189.
29. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1990;1044:275-283.
30. Mackness IM, Abbott C, Arrol S, et al. The role of high-density lipoprotein and lipid soluble vitamins in inhibiting low-density lipoprotein oxidation. Biochem J. 1993;294:829-834.
31. Hasselwander O, McEneny J, McMaster D, et al. HDL composition and HDL antioxidant capacity in patients on resular haemodialysis Atherosclerosis. 1999;143:125-133.
32. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-501.
33. Blatter Garin M-C, Abbot C, Messmer S, et al. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J. 1994;304:549-554.
34. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W, ed. Pharmacogenetics of Drug Metabolism. New York, NY: Pergamon Press; 1992:51-91.
35. Cao H, Girard-Globa A, Berthezene F, et al. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-R genetic polymorphism. J Lipid Res. 1999;40:133-139.
36. Davis HG, Richter RJ, Keifer M, et al. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet. 1996;14:334-336.
37. Mackness MI, Arrol S, Mackness B, et al. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoproteins against lipid oxidation. Lancet. 1997;349:851-852.
38. Abbott CA, Mackness MI, Kumar S, et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. 1995;15:1812-1818.
39. McElveen J, Mackness MI, Colley CM, et al. Distribution of paraoxon hydrolytic activity in serum of patients after myocardial infarction. Clin Chem. 1986;32:671-673.
40. Ayub A, Mackness MI, Arrol S, et al. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. 1999;19:330-335.
41. Secchiero S, Mussap M, Zaninotto M, et al. Serum arylesterase (paraoxonase) activity following myocardial infarction. Clin Chem Acta. 1989; 183:71-76.
42. Kunitake ST, Jarvis MR, Hamilton RL, et al. Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc Natl Acad Sci U S A. 1992;89: 6993-6997.
43. Watson AD, Navab M, Hama SY, et al. Effect of platelet activating factor acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995;95:774-782.
44. Graham A, Hassall DG, Rafique S, et al. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis. 1997;135:192-204.
45. Garner B, Waldeck AR, Witting PK, et al. Oxidation of high density lipoproteins, II: evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem. 1998; 273:6088-6095.